McInnes N, Hall S, Hramiak I, et al. - A short-term intervention with insulin glargine, sitagliptin/metformin, and lifestyle approaches for type 2 diabetes was put to test to gauge the impact on remission and relapse. Findings revealed that the primary outcome was not statistically significant but the tested approach merits further exploration with further optimization of its components.

• An open multicenter trial of 102 patients with type 2 diabetes who were randomized to 1) a 12-week intervention with sitagliptin/metformin, insulin glargine and lifestyle therapy, or 2) control group.

• With the fasting plasma glucose/oral glucose tolerance test relapse criteria included, a hazard ratio (HR) of 0.72 was noted for relapse in the intervention vs control group (primary analysis), and there was no significant difference in the number of participants remaining in remission between treatment groups at 24, 36, 48, and 64 weeks.

• Without these criteria (supplementary analyses), HR of relapse was estimated to be 0.60, and there was a significantly higher (26 vs 10%) number of participants remaining in remission in the intervention group at 36 weeks.